{"result": {"id": "cecd926c-00f5-4e65-a077-3e48c02e8e49", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Irbesartan Research and Cardiovascular Studies Community\",\n    \"summary\": \"This community is centered around the study of Irbesartan, a medication for diabetic nephropathy, and its effects, as well as broader cardiovascular research. Key entities include the New England Journal of Medicine (N Engl J Med), researchers like PARVING HH, LEHNERT H, and BROCHNER-MORTENSEN J, who have studied Irbesartan's effects, and other researchers involved in cardiovascular outcomes and risk reduction studies. The community is interconnected through research publications, collaborations, and shared focus areas, highlighting the significance of Irbesartan in diabetic nephropathy treatment and the broader implications of cardiovascular research.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the community's focus on critical health issues like diabetic nephropathy and cardiovascular diseases, which have significant implications for patient care and treatment strategies.\",\n    \"findings\": [\n        {\n            \"summary\": \"Central Role of Irbesartan in Diabetic Nephropathy Research\",\n            \"explanation\": \"Irbesartan is a focal point of this community, with multiple researchers studying its effects on diabetic nephropathy, particularly in type 2 diabetes patients. This highlights the medication's importance in managing a common and serious complication of diabetes. [Data: Entities (1327, 1324, 1325, 1326, 1331,+more); Relationships (1110, 1111, 1112, 1116,+more)]\"\n        },\n        {\n            \"summary\": \"New England Journal of Medicine as a Key Platform\",\n            \"explanation\": \"The New England Journal of Medicine (N Engl J Med) serves as a critical platform for publishing high-impact research within this community, including studies on Irbesartan and high-dose atorvastatin after stroke or transient ischemic attack. Its role underscores the community's contribution to advancing medical knowledge and clinical practice. [Data: Entities (1328, 3170,+more); Relationships (1113, 2701,+more)]\"\n        },\n        {\n            \"summary\": \"Collaborative Research Efforts\",\n            \"explanation\": \"The community exhibits strong collaborative ties, with researchers like STEG P G, MILLER M, and BHATT D L working together on cardiovascular risk reduction studies. These collaborations enhance the depth and breadth of research findings, contributing to more comprehensive understanding and treatment strategies. [Data: Relationships (2638, 2658, 5032,+more)]\"\n        },\n        {\n            \"summary\": \"Focus on Cardiovascular and Stroke Prevention\",\n            \"explanation\": \"Beyond Irbesartan, the community is actively involved in cardiovascular and stroke prevention research, as evidenced by studies on high-dose atorvastatin and lipid management. This broad focus addresses critical areas of public health concern. [Data: Entities (3158, 3162, 3169,+more); Relationships (2690, 2699,+more)]\"\n        },\n        {\n            \"summary\": \"International Research Contributions\",\n            \"explanation\": \"The community includes researchers from various countries, such as ZONG WENYI, YANG WENYING, and XIANG HONGDING, indicating the global relevance and impact of its research topics. This diversity enriches the community's perspectives and findings. [Data: Entities (1350, 1351, 1352); Relationships (1117, 1118, 1119)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752169011, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 729, "prompt_tokens": 5289, "total_tokens": 6018, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1472}, "prompt_cache_hit_tokens": 1472, "prompt_cache_miss_tokens": 3817}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        },\n        {\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        },\n        {\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        },\n        {\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }\n    ]\n}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n1327,IRBESARTAN,\"A medication studied for its effect on diabetic nephropathy\"\"\",10\r\n1328,N ENGL J MED,\"The *New England Journal of Medicine (N Engl J Med)* is a prestigious medical journal renowned for publishing high-impact clinical research. It has featured significant studies such as one investigating the effects of irbesartan on diabetic nephropathy and another examining the use of high-dose atorvastatin following a stroke or transient ischemic attack. As a leading publication in the medical field, *N Engl J Med* is recognized for its rigorous peer-review process and its role in disseminating influential research that shapes clinical practice and guidelines. The journal covers a broad spectrum of medical topics, contributing to advancements in patient care and treatment strategies worldwide.\",9\r\n1324,PARVING HH,\"**PARVING HH** is a researcher known for their involvement in studies investigating the effects of irbesartan on diabetic nephropathy, particularly in patients with type 2 diabetes. Their work focuses on understanding how irbesartan, an angiotensin II receptor antagonist, may influence the progression or management of diabetic nephropathy, a common complication of diabetes that affects kidney function. The repeated emphasis on this specific area of research across multiple descriptions highlights PARVING HH's dedicated focus on exploring therapeutic interventions for diabetic kidney disease in type 2 diabetic patients. The consistency in the provided descriptions confirms their role in this field without any contradictory information.\",4\r\n1325,LEHNERT H,\"**LEHNERT H** is a researcher who has been involved in studies examining the effects of irbesartan on diabetic nephropathy in patients with type 2 diabetes. The research focuses on understanding how irbesartan, an angiotensin II receptor blocker, impacts the progression or management of diabetic nephropathy, a common complication of type 2 diabetes. Both descriptions highlight LEHNERT H's involvement in this specific area of study, indicating a consistent focus on the therapeutic potential of irbesartan for this patient population. The repeated emphasis on this topic suggests that LEHNERT H has contributed to research efforts aimed at improving outcomes for individuals with type 2 diabetes and associated kidney disease. No contradictions were found between the provided descriptions.\",3\r\n1326,BROCHNER-MORTENSEN J,\"**BROCHNER-MORTENSEN J** is a researcher known for their involvement in studies investigating the effects of irbesartan on diabetic nephropathy, particularly in patients with type 2 diabetes. Their work focuses on understanding how irbesartan, an angiotensin II receptor antagonist, may influence the progression or management of diabetic nephropathy, a common complication of diabetes that affects kidney function. The repeated emphasis on this specific area of research highlights BROCHNER-MORTENSEN J's expertise and contributions to the field of nephrology and diabetes care. Their studies aim to provide insights into potential therapeutic interventions for improving outcomes in patients with type 2 diabetes and associated kidney disease.\",3\r\n1331,CLARKE WR,\"**CLARKE WR** is a researcher who has been involved in studies investigating the renoprotective effects of irbesartan, particularly in patients with nephropathy resulting from type 2 diabetes. The research focuses on assessing how irbesartan, an angiotensin II receptor blocker, may help protect kidney function in this high-risk patient population. Both descriptions highlight CLARKE WR's contribution to understanding the therapeutic potential of irbesartan in mitigating kidney damage associated with diabetic nephropathy. The consistent emphasis on renoprotection suggests a specialized interest in cardiovascular and renal outcomes in diabetes.  \n\nThe summaries align without contradiction, reinforcing CLARKE WR's role in this specific area of medical research. The work underscores the importance of targeted therapies, such as irbesartan, in managing complications of type 2 diabetes. No discrepancies were found between the provided descriptions, resulting in a coherent overview of the researcher's focus.  \n\n(Word count: 149)\",3\r\n1350,ZONG WENYI,\"Researcher involved in the Chinese study on irbesartan for type 2 diabetes\"\"\",1\r\n1351,YANG WENYING,\"Researcher involved in the Chinese study on irbesartan for type 2 diabetes\"\"\",1\r\n1352,XIANG HONGDING,\"Researcher involved in the Chinese study on irbesartan for type 2 diabetes\"\"\",1\r\n3167,BOGOUSSLAVSKY J,Bogousslavsky J is a co-author of a study on high-dose atorvastatin after stroke or transient ischemic attack,2\r\n3168,CALLAHAN A 3RD,Callahan A 3rd is a co-author of a study on high-dose atorvastatin after stroke or transient ischemic attack,2\r\n3170,HIGH-DOSE ATORVASTATIN AFTER STROKE OR TRANSIENT ISCHEMIC ATTACK,High-dose atorvastatin after stroke or transient ischemic attack is the focus of the study published in N Engl J Med,1\r\n4758,EUR HEART J CARDIOVASC PHARMACOTHER,\"Eur Heart J Cardiovasc Pharmacother is a European cardiology pharmacology journal.\"\"\",1\r\n3158,AMARENCO P,\"**AMARENCO P** is a researcher specializing in cardiovascular and cerebrovascular health, with a focus on lipid management and stroke prevention. Their work includes conducting meta-analyses on the efficacy of statins in reducing stroke risk, as well as investigating the role of high-dose atorvastatin in patients who have experienced a stroke or transient ischemic attack (TIA). By examining both broad statin use and specific high-dose applications, AMARENCO P contributes to advancing understanding of lipid-lowering therapies in stroke prevention. Their research spans systematic reviews and clinical studies, aiming to optimize treatment strategies for at-risk populations. Overall, their work underscores the importance of statins in secondary stroke prevention and highlights the potential benefits of intensive lipid management in post-stroke care.\",5\r\n3162,LANCET NEUROL,\"**LANCET NEUROL** (also referred to as *The Lancet Neurology*) is a medical journal that publishes research on stroke prevention and lipid management. It has featured studies focusing on the role of lipid management in preventing stroke, highlighting its commitment to advancing knowledge in neurology and related fields. The journal serves as a platform for high-quality research, contributing to clinical and scientific discussions on neurological disorders and their treatment. Both descriptions emphasize its focus on stroke prevention and lipid management, reinforcing its reputation as a key resource in the field of neurology.\",4\r\n3112,STEG P G,Steg P G is a researcher involved in cardiovascular outcomes studies>,4\r\n3130,MILLER M,\"**Summary of MILLER M:**  \n\nMILLER M is a researcher specializing in cardiovascular risk reduction studies, with a particular focus on investigations involving icosapent ethyl. Their work contributes to the broader field of cardiovascular health, specifically examining the potential benefits and applications of icosapent ethyl in mitigating cardiovascular risks. The two provided descriptions align, both emphasizing MILLER M's involvement in this area of research. No contradictions are present in the given data.  \n\nIn summary, MILLER M is an active researcher whose expertise lies in cardiovascular risk reduction, particularly through studies related to icosapent ethyl. Their contributions advance understanding in this critical area of medical science.  \n\n*(Word count: 98)*\",4\r\n3111,SCHWARTZ G G,Schwartz G G is a researcher involved in cardiovascular outcomes studies>,3\r\n1329,LEWIS EJ,\"**LEWIS EJ** is a researcher known for his involvement in studies investigating the renoprotective effects of irbesartan, particularly in patients with nephropathy caused by type 2 diabetes. His work focuses on evaluating how irbesartan, an angiotensin II receptor blocker, can protect kidney function and slow the progression of kidney disease in diabetic patients. The research highlights the potential therapeutic benefits of irbesartan in managing diabetic nephropathy, a common complication of type 2 diabetes. Both descriptions emphasize his contribution to this specific area of study, underscoring the consistency and significance of his findings.  \n\nIn summary, LEWIS EJ's research centers on the renoprotective properties of irbesartan, with a clear emphasis on its application for patients suffering from type 2 diabetes-related nephropathy. His work contributes to a deeper understanding of treatment options for diabetic kidney disease.\",4\r\n1330,HUNSICKER LG,\"**HUNSICKER LG** is a researcher primarily known for their involvement in studies examining the renoprotective effects of irbesartan, particularly in patients with nephropathy resulting from type 2 diabetes. Their work focuses on investigating how irbesartan, an angiotensin II receptor blocker, may help protect kidney function in this high-risk patient population. The research underscores the potential therapeutic benefits of irbesartan in slowing the progression of diabetic nephropathy, a common complication of type 2 diabetes. Both descriptions highlight HUNSICKER LG's contribution to this specific area of study, emphasizing a consistent focus on the drug's renoprotective properties. No contradictions were found between the provided descriptions, as they collectively reinforce the researcher's dedication to understanding irbesartan's role in managing diabetic kidney disease.\",3\r\n3113,SZAREK M,Szarek M is a researcher involved in cardiovascular outcomes studies>,2\r\n3129,BHATT D L,Bhatt D L is a researcher involved in cardiovascular risk reduction studies>,2\r\n3166,LABREUCHE J,Labreuche J is a co-author of a study on lipid management in the prevention of stroke,2\r\n3171,ZHANG XIAOLONG,,2\r\n4483,BECKETT NS,Researcher involved in studies on hypertension treatment in elderly patients,3\r\n4493,N ENGLJMED,\"The New England Journal of Medicine, a prestigious medical journal\",3\r\n4784,STEG PG,\"Researcher involved in a study on cardiovascular risk reduction with icosapent ethyl\"\"\",2\r\n3169,STROKE PREVENTION,Stroke prevention is the focus of the study published in Lancet Neurol,1\r\n4484,PETERS R,Researcher involved in studies on hypertension treatment in elderly patients,2\r\n4485,FLETCHER AE,Researcher involved in studies on hypertension treatment in elderly patients,2\r\n4783,BHATT DL,\"Researcher involved in a study on cardiovascular risk reduction with icosapent ethyl\"\"\",3\r\n4800,ICOSAPENT ETHYL STUDY,\"A clinical trial studying icosapent ethyl for hypertriglyceridemia\"\"\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\r\n1113,IRBESARTAN,N ENGL J MED,The study on irbesartan and diabetic nephropathy was published in the N Engl J Med journal,19\r\n1110,PARVING HH,IRBESARTAN,Parving HH studied the effect of irbesartan on diabetic nephropathy,14\r\n1111,LEHNERT H,IRBESARTAN,Lehnert H studied the effect of irbesartan on diabetic nephropathy,13\r\n1112,BROCHNER-MORTENSEN J,IRBESARTAN,Brochner-Mortensen J studied the effect of irbesartan on diabetic nephropathy,13\r\n1116,IRBESARTAN,CLARKE WR,Clarke WR studied the renoprotective effect of irbesartan,13\r\n1117,IRBESARTAN,ZONG WENYI,Zong Wenyi studied irbesartan for type 2 diabetes,11\r\n1118,IRBESARTAN,YANG WENYING,Yang Wenying studied irbesartan for type 2 diabetes,11\r\n1119,IRBESARTAN,XIANG HONGDING,Xiang Hongding studied irbesartan for type 2 diabetes,11\r\n2697,BOGOUSSLAVSKY J,N ENGL J MED,Bogousslavsky J published a study in N Engl J Med,11\r\n2698,CALLAHAN A 3RD,N ENGL J MED,Callahan A 3rd published a study in N Engl J Med,11\r\n2701,N ENGL J MED,HIGH-DOSE ATORVASTATIN AFTER STROKE OR TRANSIENT ISCHEMIC ATTACK,High-dose atorvastatin after stroke or transient ischemic attack is the topic of the study published in N Engl J Med,10\r\n5000,EUR HEART J CARDIOVASC PHARMACOTHER,N ENGL J MED,Both are prestigious journals publishing cardiovascular research.,10\r\n2690,AMARENCO P,LANCET NEUROL,\"**AMARENCO P** and **LANCET NEUROL**:  \n\nAmarenco P has contributed to research in the field of stroke prevention, publishing studies and meta-analyses in *The Lancet Neurology* (Lancet Neurol). Their work includes a published study as well as meta-analyses focused on stroke prevention, both appearing in this high-impact journal. The combined descriptions highlight Amarenco P's involvement in advancing stroke-related research through original studies and comprehensive reviews, underscoring their expertise in the field and their collaboration with *The Lancet Neurology*.  \n\n(Word count: 80)\",9\r\n2638,STEG P G,MILLER M,Collaborated on cardiovascular risk reduction research,8\r\n2633,SCHWARTZ G G,STEG P G,Collaborated on cardiovascular outcomes research,7\r\n4674,LEWIS EJ,HUNSICKER LG,Co-authors on a study about the renoprotective effects of irbesartan in patients with nephropathy due to type 2 diabetes,7\r\n2636,STEG P G,SZAREK M,Collaborated on cardiovascular outcomes research,6\r\n2658,BHATT D L,MILLER M,Collaborated on cardiovascular risk reduction research,6\r\n2696,LABREUCHE J,LANCET NEUROL,Labreuche J published a study in Lancet Neurol,6\r\n2700,LANCET NEUROL,ZHANG XIAOLONG,Zhang Xiaolong edited a manuscript related to the study published in Lancet Neurol,6\r\n4660,BECKETT NS,N ENGLJMED,The journal published research by Beckett NS and colleagues,6\r\n4677,HUNSICKER LG,CLARKE WR,Co-authors on a study about the renoprotective effects of irbesartan in patients with nephropathy due to type 2 diabetes,6\r\n5032,STEG PG,MILLER M,Co-authors of a study on icosapent ethyl,6\r\n2634,SCHWARTZ G G,SZAREK M,Collaborated on cardiovascular outcomes research,5\r\n2699,LANCET NEUROL,STROKE PREVENTION,Stroke prevention is the topic of the study published in Lancet Neurol,5\r\n4658,BECKETT NS,PETERS R,Co-authors on a study about hypertension treatment in elderly patients,5\r\n4659,BECKETT NS,FLETCHER AE,Co-authors on a study about hypertension treatment in elderly patients,5\r\n5029,BHATT DL,STEG PG,Co-authors of a study on icosapent ethyl,5\r\n4661,PETERS R,FLETCHER AE,Co-authors on a study about hypertension treatment in elderly patients,4\r\n5031,BHATT DL,ICOSAPENT ETHYL STUDY,Bhatt DL was a researcher in the icosapent ethyl study,4\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_f93fbea2c48c7f86c7cbcf085f73c9daeb1de0bb89d5a8de43088d56fa1b56c1_v2"}